Candel Therapeutics, Inc. (NASDAQ:CADL) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) have been assigned a consensus rating of “Moderate Buy” from the eight analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, four have given a buy rating and two have issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $18.3333.

Several analysts have commented on CADL shares. Wall Street Zen lowered shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Bank of America cut shares of Candel Therapeutics from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $13.00 to $7.00 in a report on Wednesday, September 3rd. Lifesci Capital initiated coverage on Candel Therapeutics in a report on Tuesday, October 21st. They set an “outperform” rating and a $16.00 price objective for the company. Citigroup decreased their target price on Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research report on Friday, November 14th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $23.00 price target on shares of Candel Therapeutics in a research report on Monday, September 29th.

Hedge Funds Weigh In On Candel Therapeutics

Several large investors have recently modified their holdings of CADL. Corebridge Financial Inc. boosted its holdings in Candel Therapeutics by 29.4% in the 1st quarter. Corebridge Financial Inc. now owns 13,933 shares of the company’s stock worth $79,000 after buying an additional 3,163 shares during the period. Taylor Financial Group Inc. grew its position in shares of Candel Therapeutics by 36.0% in the third quarter. Taylor Financial Group Inc. now owns 13,600 shares of the company’s stock valued at $69,000 after purchasing an additional 3,600 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of Candel Therapeutics by 128.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 7,901 shares of the company’s stock valued at $40,000 after purchasing an additional 4,439 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Candel Therapeutics by 37.7% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,748 shares of the company’s stock valued at $95,000 after purchasing an additional 4,583 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Candel Therapeutics by 36.9% during the 2nd quarter. JPMorgan Chase & Co. now owns 19,533 shares of the company’s stock worth $99,000 after purchasing an additional 5,270 shares in the last quarter. Hedge funds and other institutional investors own 13.93% of the company’s stock.

Candel Therapeutics Stock Up 1.3%

Shares of NASDAQ:CADL opened at $5.33 on Monday. The company has a market capitalization of $292.62 million, a PE ratio of -9.35 and a beta of -0.92. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.25 and a quick ratio of 8.25. The business has a fifty day moving average price of $5.21 and a two-hundred day moving average price of $5.49. Candel Therapeutics has a 1 year low of $4.25 and a 1 year high of $14.60.

Candel Therapeutics (NASDAQ:CADL) last released its earnings results on Thursday, November 13th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Analysts forecast that Candel Therapeutics will post -1.47 earnings per share for the current year.

About Candel Therapeutics

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.